Vutrisiran (Amvuttra®). HTA ID: 23035

Assessment Status Rapid Review complete
HTA ID 23035
Drug Vutrisiran
Brand Amvuttra®
Indication Indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy
Assessment Process
Rapid review commissioned 06/07/2023
Rapid review completed 03/08/2023
Rapid review outcome A full HTA is not recommended. The NCPE recommends that vutrisiran not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.